IL241193A0 - Preparations including thienopyrimidine and thienopyridine compounds and their uses - Google Patents
Preparations including thienopyrimidine and thienopyridine compounds and their usesInfo
- Publication number
- IL241193A0 IL241193A0 IL241193A IL24119315A IL241193A0 IL 241193 A0 IL241193 A0 IL 241193A0 IL 241193 A IL241193 A IL 241193A IL 24119315 A IL24119315 A IL 24119315A IL 241193 A0 IL241193 A0 IL 241193A0
- Authority
- IL
- Israel
- Prior art keywords
- thienopyrimidine
- compositions
- methods
- thienopyridine compounds
- thienopyridine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 title 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical compound C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780099P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/022750 WO2014164543A1 (en) | 2013-03-13 | 2014-03-10 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL241193A0 true IL241193A0 (en) | 2015-11-30 |
Family
ID=51529943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL241193A IL241193A0 (en) | 2013-03-13 | 2015-09-06 | Preparations including thienopyrimidine and thienopyridine compounds and their uses |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9216993B2 (enExample) |
| EP (1) | EP2968342B1 (enExample) |
| JP (2) | JP2016512514A (enExample) |
| KR (1) | KR20150130389A (enExample) |
| CN (1) | CN105188705A (enExample) |
| AU (1) | AU2014249233A1 (enExample) |
| BR (1) | BR112015022602A2 (enExample) |
| CA (1) | CA2904612A1 (enExample) |
| IL (1) | IL241193A0 (enExample) |
| MX (1) | MX2015011576A (enExample) |
| WO (1) | WO2014164543A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ706857A (en) * | 2012-09-28 | 2018-05-25 | Ignyta Inc | Azaquinazoline inhibitors of atypical protein kinase c |
| BR112015022602A2 (pt) | 2013-03-13 | 2017-07-18 | Univ Michigan Regents | composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos |
| US10246464B2 (en) | 2014-09-09 | 2019-04-02 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US10526341B2 (en) * | 2014-11-19 | 2020-01-07 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| EP3302057A4 (en) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2017132398A1 (en) * | 2016-01-26 | 2017-08-03 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia |
| KR102419524B1 (ko) * | 2016-03-16 | 2022-07-08 | 쿠라 온콜로지, 인크. | 메닌-mll의 가교된 이환식 억제제 및 사용 방법 |
| EP3429591B1 (en) * | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| US10899738B2 (en) | 2016-05-02 | 2021-01-26 | The Regents Of The University Of Michigan | Piperidines as menin inhibitors |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| ES2831084T3 (es) * | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CN109715634B (zh) * | 2016-09-14 | 2022-09-27 | 詹森药业有限公司 | Menin-mll相互作用的稠合二环抑制剂 |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| CA3033239A1 (en) * | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| ES2872003T3 (es) * | 2016-09-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Inhibidores espirobicíclicos de la interacción de menina-MLL |
| EA039109B1 (ru) * | 2016-12-07 | 2021-12-06 | Кура Онколоджи, Инк. | Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения |
| KR102513564B1 (ko) * | 2016-12-15 | 2023-03-22 | 얀센 파마슈티카 엔.브이. | 메닌-mll 상호작용의 아제판 억제제 |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| KR20190133224A (ko) | 2017-03-31 | 2019-12-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 공유 메닌 억제제로서의 피페리딘 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| BR112020012461A2 (pt) * | 2017-12-20 | 2020-11-24 | Janssen Pharmaceutica Nv | inibidores exo-aza espiro da interação menin-mll |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| PT3762368T (pt) | 2018-03-08 | 2022-05-06 | Incyte Corp | Compostos de aminopirazina diol como inibidores de pi3k-y |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| CA3108449A1 (en) * | 2018-08-08 | 2020-02-13 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active bridged piperidine derivative |
| JP2022502409A (ja) | 2018-10-03 | 2022-01-11 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | 低分子メニン阻害剤 |
| WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| MX2021006696A (es) * | 2018-12-06 | 2021-07-07 | Daiichi Sankyo Co Ltd | Derivado de cicloalcano-1,3-diamina. |
| EP3897630B1 (en) | 2018-12-21 | 2024-01-10 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
| CA3128377A1 (en) * | 2019-02-01 | 2020-08-06 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
| KR20220030222A (ko) | 2019-05-31 | 2022-03-10 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| KR20220034739A (ko) | 2019-05-31 | 2022-03-18 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| CN112116960B (zh) * | 2019-06-20 | 2024-10-11 | 中国石油化工股份有限公司 | 柴油加氢反应的组分含量确定方法、装置 |
| TW202126636A (zh) | 2019-09-30 | 2021-07-16 | 美商阿吉歐斯製藥公司 | 作為ｍｅｎｉｎ抑制劑之六氫吡啶化合物 |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| MX2022007652A (es) | 2019-12-19 | 2022-09-23 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal. |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| TW202204334A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| AR122159A1 (es) * | 2020-05-28 | 2022-08-17 | Novartis Ag | Inhibidores de mll1 y agentes antineoplásicos |
| EP4232020A4 (en) * | 2020-10-21 | 2024-08-07 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| JP2024518425A (ja) | 2021-05-08 | 2024-05-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換スピロ誘導体 |
| MX2023013174A (es) | 2021-05-08 | 2023-11-30 | Janssen Pharmaceutica Nv | Derivados espiro sustituidos. |
| US20240400564A1 (en) | 2021-05-14 | 2024-12-05 | Syndax Pharmaceuticals, Inc | Inhibitors of the menin-mll interaction |
| AU2022286467A1 (en) | 2021-06-01 | 2024-01-25 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES |
| BR112023025436A2 (pt) | 2021-06-03 | 2024-02-27 | Janssen Pharmaceutica Nv | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas |
| JP2024525145A (ja) | 2021-06-17 | 2024-07-10 | ヤンセン ファーマシューティカ エヌ．ベー． | がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩 |
| CN115515958B (zh) * | 2021-08-04 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| JP2025501287A (ja) * | 2021-12-31 | 2025-01-17 | 成都先▲導▼▲薬▼物▲開▼▲発▼股▲フン▼有限公司 | Ｍｅｎｉｎ阻害剤及びその用途 |
| WO2023215354A1 (en) * | 2022-05-03 | 2023-11-09 | Board Of Regents, The University Of Texas System | Menin proteolysis targeting chimeras (protacs) |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| CN116199633B (zh) * | 2022-12-27 | 2024-05-31 | 甘肃省化工研究院有限责任公司 | 一种制备瑞维鲁胺的方法 |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| EP1947103A1 (en) * | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| AU2009291783A1 (en) * | 2008-09-10 | 2010-03-18 | Alcon Research, Ltd | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| EP2459533A4 (en) * | 2009-07-30 | 2013-01-16 | Univ Singapore | SMALL MOLECULAR ISOPRENYLCYSTONE CARBOXYL METHYLTRANSFERASE HEMMER WITH POTENTIAL ANTIBODY EFFECT |
| CA2773131C (en) * | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| BR112015022602A2 (pt) | 2013-03-13 | 2017-07-18 | Univ Michigan Regents | composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos |
-
2014
- 2014-03-10 BR BR112015022602A patent/BR112015022602A2/pt not_active IP Right Cessation
- 2014-03-10 US US14/203,233 patent/US9216993B2/en active Active
- 2014-03-10 CN CN201480025177.5A patent/CN105188705A/zh active Pending
- 2014-03-10 AU AU2014249233A patent/AU2014249233A1/en not_active Abandoned
- 2014-03-10 WO PCT/US2014/022750 patent/WO2014164543A1/en not_active Ceased
- 2014-03-10 CA CA2904612A patent/CA2904612A1/en not_active Abandoned
- 2014-03-10 MX MX2015011576A patent/MX2015011576A/es unknown
- 2014-03-10 EP EP14779908.4A patent/EP2968342B1/en active Active
- 2014-03-10 KR KR1020157027855A patent/KR20150130389A/ko not_active Withdrawn
- 2014-03-10 US US14/773,686 patent/US9505781B2/en active Active
- 2014-03-10 JP JP2016501053A patent/JP2016512514A/ja not_active Withdrawn
-
2015
- 2015-09-06 IL IL241193A patent/IL241193A0/en unknown
- 2015-11-10 US US14/937,421 patent/US9505782B2/en active Active
-
2016
- 2016-10-18 US US15/296,842 patent/US10160769B2/en active Active
-
2018
- 2018-05-01 JP JP2018088243A patent/JP6670885B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2968342A4 (en) | 2016-07-27 |
| AU2014249233A1 (en) | 2015-09-24 |
| US10160769B2 (en) | 2018-12-25 |
| US9505782B2 (en) | 2016-11-29 |
| US9505781B2 (en) | 2016-11-29 |
| US20140275070A1 (en) | 2014-09-18 |
| JP2018115214A (ja) | 2018-07-26 |
| KR20150130389A (ko) | 2015-11-23 |
| US9216993B2 (en) | 2015-12-22 |
| CN105188705A (zh) | 2015-12-23 |
| US20170253611A1 (en) | 2017-09-07 |
| US20160046647A1 (en) | 2016-02-18 |
| BR112015022602A2 (pt) | 2017-07-18 |
| CA2904612A1 (en) | 2014-10-09 |
| WO2014164543A1 (en) | 2014-10-09 |
| MX2015011576A (es) | 2016-05-16 |
| JP6670885B2 (ja) | 2020-03-25 |
| EP2968342A1 (en) | 2016-01-20 |
| US20160137665A1 (en) | 2016-05-19 |
| JP2016512514A (ja) | 2016-04-28 |
| EP2968342B1 (en) | 2018-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL241193A0 (en) | Preparations including thienopyrimidine and thienopyridine compounds and their uses | |
| IL285780A (en) | Preparations of tmprss6 irna and methods of using them | |
| IL245550A0 (en) | Preparations and methods for using transposons | |
| ZA201602948B (en) | Compositions comprising a defined microbiome and methods of use thereof | |
| SG11201507158WA (en) | Stabilized polymer compositions and methods of making same | |
| EP2834322A4 (en) | BIOCHARBON COMPOSITIONS AND METHODS OF USE | |
| SG11201507867RA (en) | Antimicrobial compositions and methods of use | |
| SG10201708595YA (en) | Cenicriviroc compositions and methods of making and using the same | |
| SG11201505955PA (en) | Novel polymer compositions and methods of making and using same | |
| IL251639A0 (en) | Preparations including ohepa-15 and methods for using them | |
| IL243728A0 (en) | Rorc2 inhibitory trobicycloaryls and methods of using them | |
| EP2968244A4 (en) | COMPOSITIONS AND METHODS FOR USING ALIGAL COMPOUNDS | |
| IL239823A0 (en) | A mixture of disulfide conjugates of thianopyridine compounds, and their uses | |
| EP3033361A4 (en) | Alkoxysilane-functionalized polyacrylate compositions and methods of preparation thereof | |
| GB201520979D0 (en) | Breakers containing iron compounds and their methods of use | |
| AP2015008758A0 (en) | Antimicrobial compositions and related methods of use | |
| ZA201505825B (en) | Coating compositions and methods of use | |
| GB2517189B (en) | Footwear and methods of making footwear | |
| GB201518882D0 (en) | Agrochemical composition and method of use thereof | |
| IL243331B (en) | Methods and compositions of granular formulations | |
| GB201310349D0 (en) | Composition and method of use thereof | |
| GB201301928D0 (en) | Composition and method of use thereof | |
| HK1227934A1 (en) | Compositions and methods of using transposons | |
| AU2013904774A0 (en) | Methods and Preparation and Use of Xanthorrhoeaceae Compositions | |
| GB201319917D0 (en) | Accelerator Compositions and Methods |